Migraine drug shows promise for rare facial nerve pain
NCT ID NCT04158752
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug that blocks a pain-signaling protein (CGRP) in 26 adults with trigeminal or glossopharyngeal nerve pain caused by small fiber neuropathy or fibromyalgia. The goal was to see if it reduces pain and the need for other pain medications, while checking for side effects. The drug is already approved for migraines, so researchers wanted to see if it could help these other painful conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIGEMINAL NEURALGIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University
Durham, North Carolina, 27705, United States